Yevgeniy Khariton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2019591/publications.pdf

Version: 2024-02-01

21 1,029 12 18 papers citations h-index g-index

23 23 23 23 1425

23 23 23 1425
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	30.7	299
2	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
3	Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2017, 2, 1315.	6.1	126
4	Target Doses of Heart Failure MedicalÂTherapy and Blood Pressure. JACC: Heart Failure, 2019, 7, 350-358.	4.1	67
5	Health Status Disparities by Sex, Race/Ethnicity,Âand Socioeconomic Status in Outpatients With Heart Failure. JACC: Heart Failure, 2018, 6, 465-473.	4.1	65
6	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes inÂHeartÂFailure With Reduced EjectionÂFraction. JACC: Heart Failure, 2019, 7, 933-941.	4.1	31
7	Vaccination Trends in Patients With HeartÂFailure. JACC: Heart Failure, 2018, 6, 844-855.	4.1	30
8	Association Between Prompt Defibrillation and Epinephrine Treatment With Long-Term Survival After In-Hospital Cardiac Arrest. Circulation, 2018, 137, 2041-2051.	1.6	27
9	Association of Changes in HeartÂFailure Treatment With Patients' Health Status. JACC: Heart Failure, 2019, 7, 615-625.	4.1	20
10	Impact of Transesophageal Echocardiography onÂManagement in Patients With Suspected CardioembolicÂStroke. American Journal of Cardiology, 2014, 114, 1912-1916.	1.6	17
11	Health Status Variation Across Practices in Outpatients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004668.	2.2	15
12	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINEâ€HF</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1426-1430.	4.4	14
13	Health Status Benefits of SuccessfulÂChronic Total Occlusion Revascularization Across the SpectrumÂofÂLeft Ventricular Function. JACC: Cardiovascular Interventions, 2018, 11, 2276-2283.	2.9	11
14	Systemizing the Evaluation of Acute Heart Failure in the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006168.	2.2	7
15	Association between sacubitril/valsartan initiation and realâ€world health status trajectories over 18Âmonths in heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2670-2678.	3.1	7
16	Guidelineâ€directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clinical Cardiology, 2018, 41, 1414-1422.	1.8	5
17	Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure. Circulation: Heart Failure, 2021, 14, e008446.	3.9	5
18	Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMPâ€HF registry. ESC Heart Failure, 2021, 8, 710-713.	3.1	3

#	Article	IF	CITATIONS
19	HEALTH STATUS BENEFITS OF SUCCESSFUL CHRONIC TOTAL OCCLUSION PCI IN PATIENTS WITH DEPRESSED LEFT VENTRICULAR SYSTOLIC FUNCTION: INSIGHTS FROM THE OPEN-CTO REGISTRY. Journal of the American College of Cardiology, 2017, 69, 1326.	2.8	1
20	CURRENT MORE IMPORTANT THAN PAST: INTERPRETING SERIAL HEART FAILURE SPECIFIC HEALTH STATUS IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION. Journal of the American College of Cardiology, 2017, 69, 910.	2.8	0
21	Use Of Implantable Pulmonary Artery Pressure Monitoring To Guide Care Of Patients With Ambulatory Heart Failure; The First Three Years In A Real World, Single Center Experience. Journal of Cardiac Failure, 2022, 28, S42.	1.7	0